The methylation status of the MGMT promoter in glioblastoma serves not only as a prognostic indicator of disease outcome but also as a predictive marker for the efficacy of treatment with alkylating agents, thereby informing clinical decision-making and personalized treatment strategies (12). The gene discussed is MGMT; the disease is glioblastoma.